Related Experiment Video
Updated: Dec 12, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing
Jin Zhang1, Xiaoming Zhang2, Jianhua Liu1
1Department of Laboratory Medicine, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, China.
Insights
Rapid diagnosis of COVID-19 is crucial. This study shows that detecting IgM and IgG antibodies using an immunoassay within 3-15 days of symptom onset aids in COVID-19 diagnosis and understanding disease progression.
Area of Science:
- Immunology
- Infectious Diseases
- Epidemiology
Background:
- The COVID-19 pandemic caused by the novel coronavirus (2019-nCoV) has led to a global health crisis.
- Rapid and accurate diagnostic methods are essential for controlling the spread of COVID-19.
- Understanding the dynamics of antibody production and seroepidemiology is vital for epidemic control.
Purpose of the Study:
- To evaluate an automated chemiluminescent immunoassay for detecting serum IgM and IgG antibodies against 2019-nCoV.
- To investigate the dynamic process of antibody production in COVID-19 patients.
- To assess the seroepidemiological status in different populations.
Main Methods:
- An automated chemiluminescent immunoassay was employed to detect serum IgM and IgG antibodies.
- The study included 742 subjects.
- Antibody levels were monitored in relation to disease progression and onset of symptoms.
Main Results:
- COVID-19 patients showed positive reactivity for specific IgM and IgG antibodies between 3 to 15 days after symptom onset.
- Specific IgM and IgG antibody levels increased as the disease progressed.
- The immunoassay demonstrated high diagnostic accuracy, with areas under the ROC curves of 0.984 for IgM and 1.000 for IgG, indicating good sensitivity and specificity.
Conclusions:
- The developed antibody detection assay is sensitive and specific for diagnosing COVID-19.
- Monitoring dynamic serological changes provides insights into COVID-19 pathogenesis.
- Understanding seroepidemiology is crucial for effective public health interventions and controlling the COVID-19 epidemic.
Abstract:
Corona Virus Disease 2019 (COVID-19) has spread rapidly to more than 215 countries, with over 11.91 million reported cases and more than 540,000 deaths. Rapid diagnosis remains a bottleneck for containing the epidemic. We used an automated chemiluminescent immunoassay to detect serum IgM and IgG antibodies to the 2019-nCoV in 742 subjects, so as to observe the dynamic process of antibody production in COVID-19 disease and seroepidemiology in different populations. Patients with COVID-19 were reactive (positive) for specific antibodies within 3-15 days after onset of symptoms. Specific IgM and IgG levels increased with the progression of the disease. The areas under the receiver operating characteristic curves for IgM and IgG were 0.984 and 1.000, respectively. This antibody detection assay had good sensitivity and specificity. The understanding of the dynamic serological changes of COVID-19 patients and the seroepidemiological situation of the population will be helpful to further control the epidemic of COVID-19.
More Related Videos
07:08A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
Published on: April 6, 2021
08:21Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera
Published on: May 23, 2025